CN103108645B - Composition of chinese herbal compound or extract and use thereof - Google Patents

Composition of chinese herbal compound or extract and use thereof Download PDF

Info

Publication number
CN103108645B
CN103108645B CN201280002971.9A CN201280002971A CN103108645B CN 103108645 B CN103108645 B CN 103108645B CN 201280002971 A CN201280002971 A CN 201280002971A CN 103108645 B CN103108645 B CN 103108645B
Authority
CN
China
Prior art keywords
extract
chinese medicine
rhizoma coptidis
rat
fructus gardeniae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280002971.9A
Other languages
Chinese (zh)
Other versions
CN103108645A (en
Inventor
杨洪军
李韶菁
王永炎
黄璐琦
付梅红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Priority to CN201280002971.9A priority Critical patent/CN103108645B/en
Publication of CN103108645A publication Critical patent/CN103108645A/en
Application granted granted Critical
Publication of CN103108645B publication Critical patent/CN103108645B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • A61K36/744Gardenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718Coptis (goldthread)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are a composition of a Chinese medicinal compound or extract and a use thereof. The Chinese medicine consists of ginseng, coptis, and gardenia. Also provided is a use of the composition in preparing a medicament for treating or preventing nerve injury, neurodegenerative encephalopathy, bacterial or viral encephalitis, or depression.

Description

The composition and use thereof of a kind of Chinese medicine compound or extract
Technical field
The present invention relates to the compositions of a kind of Chinese medicine compound or extract, wherein said Chinese medicine is made up of Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae.The invention still further relates to the purposes of said composition in the medicine of preparation treatment or prevention brain and nerve injury, nervus retrogression encephalopathy, bacillary or viral encephalitis or depression.
Background technology
Theory of Chinese medical science great attention to whole idea and determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, Traditional Chinese medical theory is thought, blood stasis due to qi deficiency is apoplexy the important pathogenesis, and the deficiency of vital energy is primary disease basis, and blood stasis is primary disease basic pathogenesis, is the core that development occurs primary disease, and blood circulation promoting and blood stasis dispelling is the basic rule for the treatment of of treatment primary disease.Blood stasis due to qi deficiency disease only sees the apoplexy sequela phase in traditional understanding, Blood rheology is also only for sequela patient, Qing Dynasty well-known doctor Wang Qingren BUYANG HUANWU TANG represents prescription (Zhang Meikui, Yin Ling, the progress of Zhang Xuewen Buyang Huanwu Decoction in Treating cerebral infarction, China's TCM basis medical journal, 2002,8 (9): 74-78).And there is not been reported to adopt QI invigorating, removing toxic substances method for the treatment of and relevant treatment by Chinese herbs brain and nerve injury disease.
Alzheimer disease (senile dementia, SD), also known as Alzheimer (Alzheimer disease, AD) be a kind of central nervous system degenerative disease damaged based on Progressive symmetric erythrokeratodermia cognitive disorder and memory ability, and with many-sided exceptions such as motion in various degree, cognition, language and personalities.The clinical manifestation of AD is dementia syndrome, with hypomnesis, personality degeneration for feature.The main pathological change of AD is cerebral cortical atrophy, neurocyte and synapse is lost in a large number, neurofibrillary tangle, extracellular senile plaque and cerebrovascular amyloidosis.At present basic Therapeutic Method be there is no to senile dementia.Current treatment alzheimer disease molecular mechanism and relevant plant amedica have: 1) acetylcholinesteraseinhibitors inhibitors Huperzine A; 2) excitatory amino acid and peptide class mediator regulator, as leaf autumn alkali; 3) amyloid-beta (A β) processbearing astrocyte and deposition is disturbed, as ginkgetin, salvianolic acid, emodin, Sarsasapogenin etc.4) antioxidation and scavenging free radicals medicine, the extract tea polyphenols, Folium Ginkgo extract, ginsenoside, bilobalide etc. of radix Salviae Miltiorrhizae water extract salvianolic acid, Folium Camelliae sinensis; 5) microcirculation is improved, as TANSHINONES and danshensu; 6) calcium antagonist, as apigenin.
Vascular dementia (Vascular Demenia, be called for short VD) be because a series of cerebrovascular factor causes the general name of the chronic brain syndrome caused by brain tissue damage, be occur on cerebrovascular basis based on memory, cognitive dysfunction, or a kind of disease of acquired intelligent persistence infringement with language, space technical ability and emotion or personality disorder.Clinical in hypomnesis, the Progressive symmetric erythrokeratodermia obstacle of abilities such as calculating, judge, be directed and spirit, behavior is feature, is the commonly encountered diseases of mid-aged population, frequently-occurring disease.The definite pathomechanism of VD still imperfectly understands at present, it is generally acknowledged, cerebrovascular disease causes local brain tissue inflammation, metabolism disorder and oxidative stress loss, damage the cerebral tissue of enough capacity, the senior function of nervous system, particularly focus such as grievous injury memory and cognition are more prone to occur dementia symptom when relating to frontal lobe, temporal lobe and limbic system.Treatment VD Chinese medicine compound have: Rhizoma Coptidis toxic materials clearing away decoction, DANGGUI SHAOYAO SAN, dihuang drink, TIANZHI KELI, clever holy capsule, ginseng fiber crops Cognex, LIUWEI DIHUANG TANG, add taste GUIPI TANG, BUYANG HUANWU TANG etc.And there is not been reported to adopt QI invigorating, removing toxic substances method for the treatment of and relevant Chinese medicine.
Parkinson disease (Parkinson disease, PD) have another name called Parkinsonism, and in being, the common central system disorder of old people, clinical manifestation is static tremor, bradykinesia, myotonia and posture abnormal gait etc.Pathogenesis is dopamine (DA) nervous system pathological changes in maincenter nigro-striatal pathway, causes striatum DA to lack, causes somatic movement dysfunction.DOPAMINE CONTENT IN RABBIT reduces, and acetylcholine will superexcitation, two kinds of mediator disequilibriums, causes neurally can't help producing tetanic, the symptom such as to tremble with muscular tissue.At present, parkinson disease there is no radical cure medicine, and Western medicine levodopa (madopar), Ergolactin, Ergota card woods etc. are clinical common medicines, but effect is unstable, and toxic and side effects is comparatively large, and late result is not also affirmed.The clinical common method for the treatment of of Chinese medicine and common drug as follows: 1) tonifying liver is empty, town liver endogenous wind stopping: adopt Rhizoma Gastrodiae, Colla cornus cervi, Radix Asparagi, Radix Ophiopogonis, Carapax Trionycis, Carapax et Plastrum Testudinis, Radix Paeoniae Alba, Radix Glycyrrhizae etc. to be used as medicine; 2) the kidney invigorating is empty, replenishing essence QI invigorating: Fructus Corni, Fructus Schisandrae Chinensis; 3) replenishing vital essence and blood, tonifying brain with essence: adopt Herba Cistanches, Radix Angelicae Sinensis, Arillus Longan, Fructus Jujubae etc.; 4) blood circulation promoting and blood stasis dispelling: Radix Notoginseng, Squama Manis, Radix Salviae Miltiorrhizae, Scorpio.Chen Jianzong etc. find that the Chinese medicine of the nourishing liver and kidney of the compositions such as Fructus Lycii, Herba Cistanches, Radix Polygoni Multiflori can improve PD rat brain striatum DA; 3,4-dihydroxyphenyl acetic acid (DOPAC); NE; 5-HT equal size; and (Chen Jianzong, Guo Jianying, grandson wait quietly, and Vascular Parkinsonism 40 example is treated in the ruling by law of nourishing liver and kidney calming wind and dredging collateral, Journal of Traditional Chinese Medicine to have certain protective effect to nerve nucleus such as black substance, locus coeruleus, nucleus raphes dorsalises; 2002,43 (7): 528-529).The researchs such as what builds up find by Fructus Lycii, Herba Taxilli, Rhizoma Gastrodiae, Ramulus Uncariae Cum Uncis, what Bombyx Batryticatus etc. formed has enriching yin and nourishing kidney, the Chinese medicinal formulae of Tongluo Jiedu effect obviously can reduce PD rat brain release active oxygen (ROS), malonaldehyde (MDA) content, make glutathion (GSH), glutathione peroxidase (GSH-PX), the Free-radical ring opening polymerization content such as superoxide dismutase (SOD) rise, there is raising antioxidant ability of organism, how the effect alleviating radical pair body injury (builds up, Yuan Canxing, Li Yaming etc., nourishing the liver and kidney Tongluo Jiedu Chinese medicine is on the impact of Rat Model with Parkinson Disease response to oxidative stress, Chinese Journal of New Drugs and Clinical Remedies, 2003, 22 (3): 160-163).Xu Li etc. observe endogenous wind stopping relieving convulsion capsule (Radix Angelicae Sinensis, the Radix Paeoniae Alba, Scolopendra, the nourishing YIN and benefiting blood such as Scorpio, endogenous wind stopping dredging collateral Chinese medicine forms) treatment qi and blood deficiency experimental PD mice, find that it can significantly increase DA in PD mouse brain, DOPAC, the content of 4-hydroxy-3-methoxy-.alpha.-toluic acid. (HVA), and mouse limb can be reduced to tremble intensity, shorten and tremble the persistent period, therefore think that endogenous wind stopping relieving convulsion capsule has preventive and therapeutic effect (Xu Li to PD, Wei Cuie, Liu Jianxun etc., Xifeng Zhijing Capsule is to the Parkinsonian preventive and therapeutic effect of mouse experiment, new Chinese medicine and clinical pharmacology, 2005, 2:87-90).And there is not been reported to adopt QI invigorating, removing toxic substances method for the treatment of and relevant Chinese medicine.
Depression is commonly referred to as a kind of dysthymic disorder, mainly, bradyphrenia, language and behavior low with mental state are reduced to the syndrome of principal character, and main manifestations is depressed, interest attenuating, pessimism, retardation of thinking, shortage initiative, self-accusation are poor from crime, diet, sleep, worry oneself to suffer from various disease, feel whole body many places discomfort, suicidal thought and behavior can appear in severe patient.Depression has the features such as sickness rate is high, prevalence is high, relapse rate is high, homicide rate is high and awareness is low, treatment rate is low.The depression cause of disease is complicated, and the pathomechanism hypothesis of existing research at present has several as follows: 1) Monoamine Metabolism is abnormal, and depression is due in brain caused by some position monoamine neurotransmitter deficiency; 2) function of receptors changes, and antidepressants suppress presynaptic monoamine transmitters picked-up to be acute effect, and it is then a kind of chronic adaptations that postsynaptic receptor sensitivity reduces; 3) neuroendocrine disturbance, research finds that the dysfunction of depressed generation and hypothalmus-pituitary-adrenal axis (HPA), hypothalamic-pituitary-thyroid axis (HPT), Hypothalamus-pituitary-growth hormone axle (HPGH) etc. and serum cholesterol level reduce, and serum estrogen levels declines relevant.Current antidepressants are mainly containing 3 kinds of characteristics in varying degrees, namely have excitation to psychomotor, strengthen drive, enliven emotion and to angst resistance effect.It is mainly divided into five large classifications: oxidase inhibitor, tricyclic antidepressant (TCAs, as Tatinol), tetracyclic antidepressants, novel antidepressant is if selectivity 5-is through reuptake inhibitors (SSRIs, as fluoxetine), selectivity NRI, 5-hydroxy tryptamine and norepinephrine reuptake double inhibitor (SNRIs, as venlafaxine), norepinephrine and specific 5-are through reuptake inhibitors (NaSSAs, as mirtazapine), norepinephrine and dopamine reuptake inhibitor, plant amedica extract etc.But mostly have that narrow, the side effect of antidepressant spectrum is large, medicine valency is high and the feature such as easy recurrence.
Meningitis can be divided into bacillary and aseptic two class.Bacterial meningitis is the inflammation caused due to bacteriological infection pia mater encephali, and be the serious infectious disease of a kind of intracranial, often can occur together encephalitis and brain abscess.Say from nosetiology angle and comprise two large classes, a class is the meningitis (being called for short: change brain) that various suppurative bacterium infects, as: the meningitis that meningococcus, Diplococcus pneumoniae, influenza, haemophilus etc. infect; Another kind of is the meningitis of mycobacterium tuberculosis infection.Clinical application is antibacterials associating hormone therapy mainly.Aseptic meningitis refers to that CSF smear and antibacterial culturing are recessive meningitis.General aseptic meningitis mostly is caused by viral infection.Viral encephalitis refers to the brain parenchyma inflammation caused by viral infection, often shows as heating, headache, tic, disturbance of consciousness and meningeal irritation symptom etc., can cause central nervous system's focal lesion.Viral encephalitis prognosis is not good, and mortality rate is high, often leaves serious sequela.Clinical commonly used drug is 1) hormones, as adrenocortical hormone dexamethasone; 2) antiviral purines, as acycloguanosine or vidarabine; 3) antiviral cell factor class, interferon; 4) nutrition class, as citicoline, vitamin B6, vitamin E, piracetam, pantothenic acid etc. improve brain metabolism, also in conjunction with antuepileptic, should can share ataraxy medicine etc. to the patient of psychomotor excitement to there being the patient of epilepsy.
The existing medicine for brain or nerve injury disease, still exists that side effect is large, weak curative effect, the defect such as cannot to effect a radical cure.Because brain diseases is a pathophysiological process relating to too many levels, multifactor, multipath complexity; and compound Chinese medicinal preparation can have many-sided neuroprotective; there is the clinical meaning of Mutiple Targets, multidirectional adjustment, control combination, should be expected to become the comparatively effective brain of one and nerve protection medicine.
Various Radix Ginseng is the good medicine of tonify deficiency regulation of mental activities, be often used in traditional Chinese medical science prescription, Shennong's Herbal records Radix Ginseng " main tonifying five ZANG-organs, peace spirit, determine soul, spasmolytic is throbbed with fear, except pathogen, ..., happy Fructus Alpiniae Oxyphyllae ", be considered to a kind of Chinese herbal medicine with multiple drug effect, its main pharmacodynamics active component is used for brain and many sections of reports have been shown in nerve injury, as senile dementia prevention and cure, parkinson, depression, cerebral infarction, (the rivers and mountains such as the other diseases that cerebral ischemia and cerebral ischemia cause, Jiang Zhenglin, Zeng Yinming, nine kinds of panaxoside monomer anti-cerebral ischemia damnification Effect study, Pharmacology and Clinics of Chinese Materia Medica 2007, 23 (2): 19-21, Xu slanders, Liu Chunqing, Ma Tao etc., and ginsenoside Re causes the protective effect of Parkinson disease mice dopaminergic neuron to MPTP, Shenyang Pharmaceutical University's journal, and 2005,22 (1): 36-44, Panaxsaponin composition and preparation method, patent of invention, application number 200610046083.3, compound 20S-ginsenoside Rh2 is preparing in antidepressant drug, patent of invention, application number 200810043537.0).
Rhizoma Coptidis property bitter cold, tool pathogenic fire purging, dampness, removing toxic substances, effect of parasite killing, modern pharmacology research shows, it is except having strong antibacterial activity, also has the multiple pharmacotoxicological effects such as antiinflammatory, blood fat reducing, blood sugar lowering, antitumor, antiulcer, nervous system protection.Report Rhizoma Coptidis is had in Cerebral ischemia and reperfusion damage, to play protective effect (Ki-Yeon Yool by antiinflammatory action; In Koo Hwang2; Jong Dai Kim3 etc.; Antiinflammatory Effect of the Ethanol Extract of Berberis koreana in a Gerbil Modelof Cerebral Ischemia/Reperfusion Phytother.Res.2008; 22,1527-1532).
Fructus Gardeniae is the fruit of Maguireothamnus speciosus Fructus Gardeniae (Gardenia jasminoides Ellis.), and property bitter cold is nontoxic.Enter the heart, liver, lung, stomach warp.There is effect of pathogenic fire purging relieving restlessness, clearing away heat and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body.Cure mainly calentura restlessness of asrhenia type and insomnia, jaundice, gonorrhea, quench one's thirst, conjunctival congestion, pharyngalgia, haematemesis, epistaxis, dysentery, hematuria, pathopyretic ulcer, sprain and swell and ache.Clinical in diseases such as acute icterohepatitis, hemostasis, bruises.Modern pharmacology research shows, Fructus Gardeniae except having antipyretic, antibacterial, calm, analgesia, function of gallbladder promoting, antiinflammatory, stop blooding, protect the liver, except traditional pharmacological action such as soft tissue healing, also there is effect (chemical composition of Fructus Gardeniae and the pharmacological research such as antioxidation, asthma, blood fat reducing, blood pressure lowering, antiallergic, atherosclerosis, antiviral, antidepressant worry, nervous system protection, north pharmacy, 2008,5 (3): 44-45,51; Huang Shisun, Wu Shuyue, the modern pharmacological research of Fructus Gardeniae and clinical practice general introduction, internal medicine, 2010,5 (5): 534-536; Liu Guomin, Guo Suhua, Cheng Weiming, the pharmacological action of Fructus Gardeniae and Mechanism Study new development thereof, Strait Pharmaceutical Journal, 2008,20 (11): 8-10; Fructus Gardeniae extract is preparing the purposes prevented and/or treated in depressed worried medicine, Chinese invention patent, application number 200810016679.8).
The classical compound coptis chinensis Detoxication Decoction that Rhizoma Coptidis and Fructus Gardeniae share is published originally in " medical secrets of official ", is made up of, is regarded as the representative side of heat-clearing and toxic substances removing, have effect of eliminating fire and detoxication, cure mainly the card of all excess-heat fire-toxin, three burnt intenseness of heat Rhizoma Coptidis, Cortex Phellodendri, Radix Scutellariae, Fructus Gardeniae.There is report Rhizoma Coptidis toxic materials clearing away decoction for cerebropathy therapeutic, brain injury and the inflammatory that can reduce Cerebral ischemia and reperfusion invade profit (Young Sun Hwang a, Chan Young Shin b, YoungbuhmHuh etc., Hwangryun-Hae-Dok-tang (Huanglian-Jie-Du-Tang) extract and its constituentsreduce ischemia-reperfusion brain injury and neutrophil infiltration in rats.LifeSciences2002,71:2105-2117).
But the present inventor notices still to lack and can be used for QI invigorating removing toxic substances with the pharmaceutical preparation for the treatment of brain and nerve injury disease.
Summary of the invention
Present composition QI invigorating Jiedu Fang is the crucial pathogenesis for " poison damages brain network ", and employing determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, strengthening vital QI to eliminate pathogenic factors treatment traditional Chinese medical science encephalopathy propose.QI invigorating Jiedu Fang is the compound Chinese medicinal preparation having no report in the past, and it also has no report for traditional Chinese medical science brain and nerve injury prevention and treatment of diseases.QI invigorating removing toxic substances prescription is made up of Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae three taste.Wherein, Radix Ginseng is monarch drug, strongly invigorating primordial QI, Fructus Alpiniae Oxyphyllae of calming the nerves, can tonifying five ZANG-organs gas, and the treatment deficient for healthy energy is very appropriate; Rhizoma Coptidis is ministerial drug, is the non-defective unit of eliminating fire and detoxication, and with ginseng compatibility, one mends one rushes down, and brings out the best in each other; Fructus Gardeniae is adjuvant, the kind relieving restlessness that clears away heart-fire of this medicine merit, and removing pathogenic heat from blood and toxic substance from the body, the eliminating fire and detoxication of auxiliary Rhizoma Coptidis, its property flexing is descending simultaneously, drives all pathogenic fire and goes out from urine, make the heresy outlet to some extent of pyretic toxicity.This three tastes compatibility, can on the basis of righting, and validation removing toxic substances is evil, plays good synergistic therapeutic action.
It is the general pathomechanism that brain injury is fallen ill that excitatory amino acid discharges in a large number with neurotransmitter exception, oxidative stress, free radical, inflammatory cascade, mitochondria dysfunction etc.; Radix Ginseng is longer than QI invigorating, neuroprotective; Rhizoma Coptidis and Fructus Gardeniae are longer than removing toxic substances, its three kinds of compatibilities can be accomplished reasonable compatibility, mutually short complementation.
Therefore, the technical problem that the present invention solves is to provide a kind ofly can prevent or treat the Chinese medicine compound of brain and nerve injury disease or the compositions of extract.
The present invention relates to the compositions of a kind of Chinese medicine compound or extract, described Chinese medicine is made up of Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae.
As above according to compositions of the present invention, wherein the content of Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae is for being 100 parts of calculating according to gross weight: Radix Ginseng, 1-99 part, Rhizoma Coptidis, 1-99 part, Fructus Gardeniae, 1-99 part; Preferably ginseng, 2-75 part, Rhizoma Coptidis, 2-75 part, Fructus Gardeniae, 2-75 part; More preferably Radix Ginseng 3-50 part, Rhizoma Coptidis, 3-50 part, Fructus Gardeniae, 3-50 part.
As above according to compositions of the present invention, wherein the content of Radix Ginseng extract, Rhizoma Coptidis extract, Fructus Gardeniae extract is for being 100 parts of calculating according to gross weight: Radix Ginseng extract, 1-99 part, Rhizoma Coptidis extract, 1-99 part, Fructus Gardeniae extract, 1-99 part; Preferably ginseng's extract, 2-75 part, Rhizoma Coptidis extract, 2-75 part, Fructus Gardeniae extract, 2-75 part; More preferably Radix Ginseng extract 3-50 part, Rhizoma Coptidis extract, 3-50 part, Fructus Gardeniae extract, 3-50 part.
As above according to compositions of the present invention, wherein the weight ratio of Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae is 3: 2: 2-0.5, preferably 3: 2: 1, more preferably 3: 2: 2.
As above according to compositions of the present invention, wherein the weight ratio of Radix Ginseng extract, Rhizoma Coptidis extract, Fructus Gardeniae extract is 3: 2: 2-0.5, preferably 3: 2: 1, more preferably 3: 2: 2.
As above according to compositions of the present invention, it comprises Chinese medicine compound or extract such as, as active component and any one or multiple pharmaceutically acceptable carrier, antioxidant, chelating agent, filler, framework material etc.
As above according to compositions of the present invention, it can make the pharmaceutically acceptable dosage form of any one with pharmaceutically acceptable carrier according to specific needs, and such as tablet, granule, capsule, injection are as powder pin, freeze-dried powder, transfusion etc.
The invention further relates to compositions as above treat in preparation or prevent brain and nerve injury, such as cerebrovascular dementia or ischemic cerebrovascular (such as transience local cerebral ischemia outbreak, cerebral infarction or apoplexy), nervus retrogression encephalopathy, such as, purposes in the medicine of senile dementia or Parkinson's disease, bacillary or viral encephalitis or depression.
Accompanying drawing explanation
Fig. 1: the present composition to be performed the operation 24h cerebral Ischemia rat brain slice cerebral ischemia area TTC coloration result to row MCAO, A: sham operated rats; B: model group; C: positive controls (Folium Ginkgo extract Egb761 sheet group) (4mg/kg); D-F: administration group 1,2,3 (10g crude drug/kg).
Fig. 2: the present composition is on the impact (n=10) of the rat cerebral infarction volume of row MCAO Post operation 12h and 24h.
Detailed description of the invention
Further illustrate the present invention below in conjunction with embodiment, advantage and disadvantage of the present invention will be more clear along with description.But these embodiments are only exemplary, do not form any restriction to scope of the present invention.It will be understood by those skilled in the art that and can modify to the details of technical solution of the present invention and form or replace down without departing from the spirit and scope of the present invention, but these amendments and replacement all fall within the scope of protection of the present invention.
The preparation technology of Chinese medicine compound and preparation thereof
The preparation of Chinese medicine compound
The Radix Ginseng of 3: 2: 2-0.5, Rhizoma Coptidis, Fructus Gardeniae decoction pieces by part by weight, after respective pulverizing, by Rhizoma Coptidis decoction pieces powder with 50% alcohol reflux, 3h/ time, pH=2 is adjusted with concentrated hydrochloric acid after ethanol extract is concentrated, add 10%-12%NaCl solid, fully stir and make it dissolve completely, placement is spent the night, sucking filtration, precipitate, with distilling washing on a small quantity, in 50 ~ 60 DEG C of dryings, obtains Rhizoma Coptidis extract.Again Radix Ginseng, Fructus Gardeniae decoction pieces powder are decocted with water four times, each 2 hours, amount of water is 12 times of medical material amount; Collecting decoction, filters, is concentrated into the clear paste that relative density is 1.04-1.05 (50 DEG C), adding ethanol makes alcohol content reach 70%, and cold preservation (5 ~ 10 DEG C) is spent the night, and filters, filtrate recycling ethanol, and being concentrated into the clear paste that relative density is 1.32 ~ 1.35 (50 DEG C), drying under reduced pressure (70 DEG C), dried cream powder is broken into fine powder, the extract mixtures of obtained Radix Ginseng and Fructus Gardeniae, it is mixed with Rhizoma Coptidis extract, after stirring, obtains a homogeneous mixture.
The preparation of compound Chinese medicinal preparation
The preparation of Chinese medicine compound tablet
Get above-mentioned homogeneous mixture, add medicinal supplementary product starch, magnesium stearate etc. appropriate, fully after mixing, tabletting, makes the tablet containing above-mentioned Chinese medicine compound.
The preparation of Herbal compound capsule agent
Get above-mentioned homogeneous mixture, add medicinal supplementary product starch appropriate, fully incapsulate after mixing, make the capsule containing above-mentioned Chinese medicine compound.
The preparation of Chinese native medicine compound prescription pellet agent
Get above-mentioned homogeneous mixture some, add medicinal supplementary product starch appropriate, make the granule containing above-mentioned Chinese medicine compound.
The preparation of complex injection of Chinese materia medica
Get above-mentioned homogeneous mixture, inject and use pure water and polyoxyethylene sorbitan monoleate in right amount, make the injection containing above-mentioned Chinese medicine compound.
The preparation of Chinese medicine compound powder ampoule agent for injection
Get above-mentioned homogeneous mixture, inject by water-soluble pesticide right amount of auxiliary materials, make the powder ampoule agent for injection containing above-mentioned Chinese medicine compound.
The preparation method of Chinese medicine extract and preparation thereof
The preparation of Chinese medicine extract
Be the preparation method of 00110418.7 according to the patent No., obtain Radix Ginseng total saponins extract, be the preparation method of 201010156823.5 according to the patent No., obtain the jasminoidin extract that Determination of Gardenoside is 99%, be the preparation method of 200710020332.6 according to the patent No., obtain the berberine hydrochloride that content is 98%, be 3: 2: 2-0.5 mix homogeneously by above-mentioned three kinds of extracts according to the weight ratio of Radix Ginseng total saponins, berberine hydrochloride, jasminoidin, obtain mixture for subsequent use.
The preparation of Chinese medicine extract tablet
Get said mixture, add pharmaceutic adjuvant starch, magnesium stearate etc. in right amount, fully after mixing, tabletting, makes the tablet containing above-mentioned Chinese medicine extract.
The preparation of Chinese medicine extract capsule
Get said mixture, add medicinal supplementary product starch appropriate, fully incapsulate after mixing, make the capsule containing above-mentioned Chinese medicine extract.
The preparation of Chinese medicine extract granule
Get said mixture some, add medicinal supplementary product starch appropriate, make the granule containing above-mentioned Chinese medicine extract.
The preparation of Chinese medicine extraction composition injection
Get said mixture, inject and use pure water and polyoxyethylene sorbitan monoleate in right amount, make the injection containing above-mentioned Chinese medicine extract.
The preparation of Chinese medicine extract powder ampoule agent for injection
Get said mixture, inject by water-soluble pesticide right amount of auxiliary materials, make the powder ampoule agent for injection containing above-mentioned Chinese medicine extract.
Embodiment 1 present composition is tested acute focal cerebral ischemia animal protection Effect study
Acute focal cerebral ischemia in rats is set up
Adopt body weight at 250-270g male SD rat, with reference to (Longa EZ such as Zea Longa, Weinstein PR, Carlson S, Cummins R.Reversible middle cerebral artery occlusion withoutcraniectomyin rats.Stroke1989; Bolt line blocking-up method in intraluminal middle cerebral artery occlusion in rats 20:84-91) set up, 10% chloral hydrate solution 400mg/kg, intraperitoneal injection of anesthesia animal.Rat dorsal position is fixed, cervical region medisection skin, each layer tissue of blunt separation, exposes right carotid (CCA).To be separated to after internal carotid artery (internalcarotid artery, ICA), external carotid artery (external carotid artery, ECA) bifurcated one section, to be carefully separated and to avoid damage vagus nerve and trachea, put line for subsequent use.Be separated homonymy external carotid artery, send about 0.8cm place's ligation at ECA.A bulldog clamp is pressed from both sides in CCA proximal part, " V " shape otch that a diameter is about 2mm is done between ECA ligation place and crotch, nylon wire is inserted ACCA gently from incision, unclamp bulldog clamp, in neck, external carotid artery furcation enters internal carotid artery, the direction that nylon wire enters intracranial to ICA is lentamente advanced, insertion depth about 18.5 ± 0.5mm is to micro-sense resistance, make nylon wire head end by MCA section start, arrive thinner anterior cerebral artery, now namely realize the blood flow obstruction of left side middle cerebral artery, ligation ICA is with fixing nylon wire and prevent hemorrhage, layer-by-layer suture, nylon wire stump stays 1em to be longer than outside skin.
Sham operated rats only carries out preoperative anesthesia and blood vessel exclusion, not ligation and lead-in wire bolt.In operation process, room temperature remains on 24-25 DEG C, and biological functional system carries out animal breath and cardioelectric monitor.
Animal grouping and administration
SD rat is divided into six groups at random: sham operated rats, model group, Folium Ginkgo extract sheet positive controls (Ginaton Folium Ginkgo extract sheet, Egb761, Dr Willmar Schwabe), present composition administration group 1,2,3.Positive controls medication: get Folium Ginkgo extract sheet 1 (40mg) and be dissolved in 40ml normal saline, be mixed with 1mg/mL, gavage gives SD rat 1mL, and dosage is 4mg/kg.Administration group medication: gavage gives Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae decoction pieces according to the extractum obtained as aforementioned Chinese medicine compound preparation technology of weight ratio 3: 2: 0.1 (administration group 1), 3: 2: 2 (administration groups 2), 3: 2: 0.5 (administration groups 3) respectively, dosage 10g crude drug/kg.Administration group and positive controls be 10min gastric infusion before surgery anesthesia, respectively at postoperative 4,12,24h puts to death animal, carries out following indices detection.
The functional evaluation of neuroethology Bederson's method
Animal carries out neuroethology observation before execution, with reference to method (the Bederson JB of Bederson etc., PittsLH, Tsuji M, et a1., Rat middle cerebral artery occlusion:evaluation of the model anddevelopment ofa neurologic examination.Stroke1986; 17:472-476), carry Mus tail and leave ground about 1 chi, observe two forelimb situations; Rat is placed in level ground, promotes its both shoulders, observing both sides resistance has zero difference; Rat is placed in ground, observes its walking situation.Adopt Pyatyi point system (0-4 divides), mark is higher, illustrates that the damage of its neurobehavioral is more serious.The statistical result of Bederson's function score is in table 1, and between each group, data compare employing rank test, and P<0.05 thinks to have statistical significance.
The statistical result of table 1Bederson's function score ( n=10)
Note: nonparametric rank test, inspection, compare with matched group: *p<0.01; Compare with model group: #P<0.05, ##P<0.01
Conclusion: as shown in Table 1, model group comparatively sham operated rats has significant difference, modeling success (P<0.01) is described, positive controls (4mg/kg) and administration group 1,2,3 significantly can improve the nerve injury symptom (P<0.05, P<0.01) of 12h and 24h after animal focal cerebral ischemia.
To the improvement result evaluation of cerebral ischemia cerebral infarction volume
Rat sacrificed by decapitation after function score, is placed in-20 DEG C of refrigerators by the cerebral tissue of taking-up rapidly, the rearmounted room temperature environment of 10min, excision olfactory bulb, cerebellum and low brain stem after and be cut into 6 brain continuous coronal rough lumber sheets by interval 2mm shown in cerebral localization collection of illustrative plates is crown.Then the rapid 5ml that is placed in by brain sheet is containing 2%TTC (triphenyltetrazolium chloride) and 1molL -1k 2hPO 4in the solution of 0.1ml, 37 DEG C of constant temperature, lucifuges hatch 30min, and brain sheet stirs once every 5min by period.After TTC dyeing, normal structure is rose, and infarction tissue is not colored and is white.Often will organize brain sheet marshalling, preservation of taking pictures, the process of applies image analysis systems soft ware also takes statistics, and calculates the infarct size of often opening brain sheet, is multiplied by the thickness 2mm of every sheet brain sheet, and every animal all brain sheets infarct size is multiplied by thickness and is added, and is cerebral infarct volume.
Conclusion: as illustrated in fig. 1 and 2, after rat cerebral tissue's ischemic injuries, sham operated rats occurs without cerebral infarction, and model group occurs obvious infarcted region and presents TTC dyeing canescence.Administration group 1,2,3 significantly can reduce cerebral infarction ash white area, reduces cerebral infarct volume, has remarkable improvement result to cerebral infarction.
By testing the known present composition above, there is good Acute cerebral ischemia protective effect.
Embodiment 2 present composition is tested senile dementia (AD) animal protection Effect study
Amyloid-beta (A β 1-40) hatch
With physiological saline solution by A β 1-40be diluted to 2ug/ul, hatch 1 week for 37 DEG C, make it the A β becoming condensed state 1-40.
A β 1-40cause Model of Dementia in Rats to set up
Be fixed on rat stereotaxic instrument after getting the healthy male AD rat anesthesia of 250-270g, conventional preserved skin sterilization, cut skin, expose bregma, slowly condensed state A β is injected to rats with left hippocampus (be 0 point with Bregma point, AP-3.0mm, ML2.0mm, DV-2.9mm) with microsyringe 1-405 μ l, let the acupuncture needle remain at a certain point 5min, to make the abundant disperse of A β, then slowly remove pin, sew up the incision.Sham operated rats only carries out preoperative anesthesia, cuts skin, exposes bregma, does not carry out injection A β 1-40.
Experiment grouping and administration
Healthy for 250-270g male SD rat 30 is divided into sham operated rats, A β model group, Folium Ginkgo extract sheet positive controls, present composition administration group 1,2,3 at random, often organizes 5.Positive controls medication: get Folium Ginkgo extract sheet 1 (40mg) and be dissolved in 4ml normal saline, be mixed with 1mg/mL, gavage gives SD rat 1mL, and dosage is 4mg/kg.Administration group medication: gavage gives Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae decoction pieces according to the extractum obtained as aforementioned Chinese medicine compound preparation technology of weight ratio 3: 2: 0.5 respectively, dosage 20g crude drug/kg (administration group 1), 10g crude drug/kg (administration group 2) and 5g crude drug/kg (administration group 3).After model has been made, A β model group and sham operated rats have injected equal-volume normal saline, and other group gavages give corresponding medicine.
Morris water maze is tested
Postoperative 30d starts determined with Morris water.Water maze is diameter 90cm, the pond of high 40cm, depth of water 30cm, pool wall is indicated 4 place of entry, is divided into four quadrants, put a lucite circular platform in a wherein quadrant center, platform is lower than water surface 2cm, water temperature (24 ± 2) DEG C, by the uniform white plastic foam coverage of opaque thickness, peripheral pool object of reference remains unchanged.Test comprises:
1) orientation navigation test: for measuring the acquisition capability of rat to water fan official learning and memory.Last 5d, two time periods of morning and afternoon every day, each time period 4 times, respectively from four different gauge points, rat is put into water towards pool wall, in record 2min, find platform required time (escape latency).If fail to find platform in 2min after rat enters water, to be then placed on platform and to stop 10s, escape latency record 2min.Each training interval 60s.
2) space exploration test: after measuring rat association searching platform, to the hold facility of platform space position memory.After orientation navigation off-test, removed by platform in the 6th day, rat is put into water towards pool wall by an optional place of entry, crosses over the number of times of original platform position in record 2min.
Adopt one factor analysis of variance (One-Way ANOVA), P<0.05 thinks to have statistical significance.Morris water maze test result is in table 2.
Table 2 orientation navigation test in average escape latency (s, n=5)
Note: *p<0.01, ##p<0.01
Table 3Morris water maze rat space exploration experimental result ( n=5)
Note: *p<0.05, *p<0.01
As shown in Table 2, rat changes not obvious in after giving the present composition first 2 days, and from the 3rd day, model group was compared with sham operated rats: *p<0.01, illustrates modeling success; Administration group compares with A β model group: ##P<0.01, and this shows, administration group 1,2,3 obviously can shorten the latter three days average escape latency started.As shown in Table 3, administration group obviously can shorten rat space exploration incubation period, and increase and cross over original platform position number of times, therefore the present composition is to A β 1-40caused rat AD model has obvious protective effect.
Aluminium oxide causes mice Model of Dementia and medication
Laboratory animal selects the aged Kunming mouse at 22 monthly ages, male and female half and half, are divided into 6 groups at random: namely Normal group, aluminum chloride model group, aluminum chloride add Folium Ginkgo extract sheet positive controls, aluminum chloride adds present composition administration group 1,2,3.Positive controls medication: get Folium Ginkgo extract sheet 1 (40mg) and be dissolved in 4ml normal saline, be mixed with 1mg/mL, gavage gives mice 1mL, and dosage is 4mg/kg.Administration group medication: gavage gives Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae decoction pieces according to the extractum obtained as aforementioned Chinese medicine compound preparation technology of weight ratio 3: 2: 0.5 respectively, dosage 20g crude drug/kg (administration group 1), 10g crude drug/kg (administration group 2) and 5g crude drug/kg (administration group 3).To aluminum chloride distilled water solution (Shanghai Jinshan chemical plant produces, lot number 100093) the 200mg/kg body weight/day of aluminum chloride model group mice 10mg/ml, gastric infusion, continuous 90 days.While setting up Model of Dementia, Folium Ginkgo extract sheet and the present composition is given, gastric infusion, continuous 90 days to positive controls and administration group.Normal group gives same dosage normal saline.
Jumping test
TT-2 type mice diving tower procedure auto-control instrument (institute of Materia Medica,Chinese Academy of Medical Sciences development).Its diving tower reflective box is 90 × 18 × 60cm 3lucite case, is separated between 5 by lamella lucida, is copper grid at the bottom of case, in addition 36V voltage, a built-in high 3.5cm between every, and diameter is the valve rubber of 3.5cm, avoids the place of safety of electric shock as mice.Test front 3 angel mices and be familiar with laboratory environment, keep quite in indoor, temperature 25 DEG C.After mice being put into reflective box endoadaptation 5min during experiment, then pass to 0.25mA electric current, be placed in by mice on diving tower, mice has the habit of jumping off from eminence, if jumped off, is shocked by electricity and produces memory.During training, diving tower is greater than 180s person is discarded incubation period, the number of times (errors number) jumped off from platform in record mice 5min, based on errors number, mice is divided into 6 groups of (Normal group, model group, positive control Folium Ginkgo extraction sheet group, administration groups 1,2 by achievement, 3, positive control and administration 1,2,3 groups), often organize 10,6 groups of intelligent of ageing mice are on close level.Conscientiously measure mice in 5min during experiment in detail and jump off the number of times that contacts to earth (error number) from platform, learn the observation index of acquisition and memory consolidation as mice.
Adopt one factor analysis of variance (One-Way ANOVA) analysis, P<0.05 thinks to have statistical significance.Jumping test the results are shown in Table 4.
Table 4 mice Jumping test ability of learning and memory change comparison ( n=10)
Note: *p<0.05, #p<0.05, ##p<0.01
As shown in Table 4, model group compares with administration group: *p<0.05, illustrates modeling success; Administration group compares with model group: #p<0.05, ##p<0.01, shows that the present composition obviously can reduce the errors number of mice Model of Dementia, is therefore significantly improved effect to ability of learning and memory in mice.
Embodiment 3 present composition is to parkinsonian animal models protective effect research experiment
Parkinsonian animal models is set up and medication
MPTP-induced Parkinson disease mice model is made by the method for lumbar injection pesticide N,N'-dimethyl-.gamma..gamma.'-dipyridylium (paraquat, PQ).Get Kunming mouse 120 in male 7 week age, after adapting to one week, be divided into 6 groups at random, often organize 20.Blank group: gavage distilled water 10mL/kg body weight once a day, weekly intraperitoneal injection of saline 10ml/kg body weight; All the other 5 groups weekly lumbar injection P Q10mg/kg, and gavage every day colchicine, by 4 times of adult's dosage, i.e. 0.2mg/kg, continues modeling administration in 7 weeks.After modeling success, positive controls: gavage every day madopar, according to adult 7.5 times of dosage, namely presses 125mg/kg dosed administration, to continue medication to modeling one week; Administration group 1,2,3: respectively mouse stomach present composition 20g crude drug/kg, 10g crude drug/kg, 5g crude drug/kg (medication is with embodiment 2), to continue medication to modeling one week.Raise under the same terms, the behavioristics observing mice changes, and then does the content detection of mice black substance brain district monoamine neurotransmitter, and dopamine (DA), norepinephrine (NE), 5-hydroxy tryptamine (5-HT) detect.
Turn-club test
Normal mouse has climbing ability, and this needs suitable grip and sports coordination, and we adopt turn-club test to detect the dyskinesia of mice.Mice is put on transfer rod tester (Ji'an, Beijing get Er Science and Technology Ltd. YLS-4C type), puts 6 at every turn, rotate by the speed of 20 turns per minute, the number of times fallen down in record mice 3min.
Autonomic activities measures
Mice is put into the active box of autonomic activities tester, each Simultaneously test 6 mices, 1 mice in each case, puts into relief mice adaptation 3min and starts test again, after computer enters mensuration program, automatically record number of times that is movable in mice 10min and that stand by computer.
Adopt one factor analysis of variance (One-Way ANOVA) analysis, P<0.05 thinks to have statistical significance.Behavioristics's testing result is in table 5.
Table 5 behavioristics testing result ( n=20)
Note: *p<0.01, #p<0.05, ##p<0.01
As shown in Table 5, model group is compared with blank group *p<0.01, illustrates modeling success; The number of times that after giving the present composition, mice falls down from transfer rod reduces, and movable number of times obviously increases.Administration group compares with model group: #p<0.05, ##p<0.01, illustrates that the present composition significantly can improve the behavioral competence of parkinson mice.
The content detection of monoamine neurotransmitter the results are shown in Table 6.
The measurement result of table 6DA, NE, 5-HT content ( n=10)
Note: *p<0.05, *p<0.01, #p<0.05, ##p<0.01
From table 5,6, the present composition significantly can reduce the dyskinesia that PQ causes parkinson mice, reduces the excessive release of monoamine neurotransmitter, improves parkinson symptom.
Embodiment 4 present composition is to creation protective effect research experiment
Animal Model
Adopt permanent ligation bilateral common carotid arteries rat models of vascular dementia.After SD rats by intraperitoneal injection 3.5% chloral hydrate 10ml/kg anaesthetizes, dorsal position is fixed, cervical region median incision, is separated bilateral common carotid arteries, avoids damage cervical sympathetic nerve and vagus nerve, and with Line 1 by its permanent ligation, postoperative sew up wound, raises in cage.Sham operated rats is for being separated bilateral common carotid arteries, but not ligation.
Animals administer method
Operation January after, grouping administration, rat is divided into six groups at random: sham operated rats, model group, Folium Ginkgo extract sheet positive controls (4mg/kg), Chinese medicine extract administration group of the present invention 1,2,3 (20g crude drug/kg, 10g crude drug/kg and 5g crude drug/kg) (medication is with embodiment 2).
Morris water maze ability of learning and memory test experience
Water maze is diameter 90cm, the pond of high 40cm, depth of water 30cm, pool wall is indicated 4 place of entry, is divided into four quadrants, put a lucite circular platform in a wherein quadrant center, platform is lower than water surface 2cm, water temperature (24 ± 2) DEG C, by the uniform white plastic foam coverage of opaque thickness, peripheral pool object of reference remains unchanged.Test comprises:
1) course experiment is located: for measuring the acquisition capability of rat to water fan official learning and memory.Platform is placed in the centre of a certain quadrant in labyrinth, an optional place of entry in other three quadrants, every day is trained secondary in experiment, the place of entry that each employing is different, each training scheme of 1 minute.If animal not yet finds platform within 2min, then being taken by animal on platform and to make it stand above 15 seconds, if rat found platform within 2 minutes, be also allowed to condition on platform and stand 15 seconds, reef knot Shu Yici trains.Training like this five days, records escape latency and the swimming path of every animal respectively.
2) space search experiment: after measuring rat association searching platform, to the hold facility of platform space position memory.After orientation navigation off-test, in the 6th day, platform is removed, every rat only swims 2 minutes, respectively with the time of stopwatch record every rat first time through platform, i.e. incubation period, and record every rat number of times through platform in 2 minutes, if the incubation period of certain rat is shorter and more through original platform position number of times, then illustrate this rat space orientation ability and learning and memory function good.
Administration started Morris water maze laboratory after 14 days.Located course experiment before this, every rat trains 2 times every day, and training duration is 120s, continuously training 5 days, record parameters.Then carry out space search experiment, within the 6th day, remove platform, record rat incubation period and in 2 minutes by the number of times of position of platform.
Adopt one factor analysis of variance (One-WayANOVA) analysis, P<0.05 thinks to have statistical significance.Water maze laboratory the results are shown in Table 7,8,9,10.
Table 7 vascular dementia rats location course experiment escape latency ( )
Note: *p<0.05, *p<0.01, ##p<0.01
As shown in Table 7, model group compares with sham operated rats, #p<0.05, ##p<0.01, modeling success is described, administration group compares with model group, *p<0.05, *p<0.01, illustrates that the present composition significantly can reduce the escape latency of vascular dementia rats.
The table 8 vascular dementia rats location course experiment distance of swimming ( )
Note: *p<0.05, *p<0.01, ##p<0.01
Have table 8 known, model group compares with sham operated rats, #p<0.05, ##p<0.01, modeling success is described, administration group compares with model group, *p<0.05, *p<0.01, illustrates that the present composition significantly can reduce the distance of swimming in water maze laboratory of vascular dementia rats.
Table 9 vascular dementia rats space exploration experimental result ( )
Note: *p<0.05, *p<0.01
As shown in Table 9, administration group compares with model group, *p<0.05, *p<0.01, illustrate incubation period that rat gives present composition rear space explorative experiment comparatively model group obviously shorten, obviously increase through original platform number of times.
Table 10 different dosing natural law Chinese medicine of the present invention find intending VD rat platform experiment incubation period impact ( n=8)
Note: *p<0.05, *p<0.01, ##p<0.01
As shown in Table 10, administration group compares with model group, ##p<0.01, illustrates that the present composition obviously can shorten rat and find platform incubation period.
From above experimental result, after giving the present composition, obviously can improve the ability of learning and memory of vascular dementia rats.
Step-through test
Rat is put into bright room, free movable 3min in case.Do not enter darkroom person in 3min and reject (during preliminary election no power).Formally carry out learning training after 1h, it is incubation period that record rat enters the darkroom required time that gets shocked, and records in 5min and suffer number of shocks (errors number) as school grade; Repeat said process after 24h, record incubation period and errors number are as Memory result.Voltage is 36V, incubation period index with second (S) for unit.
Adopt one factor analysis of variance (One-WayANOVA) analysis, P<0.05 thinks to have statistical significance.Step-through test the results are shown in Table 11.
Table 11 vascular dementia rats step-through test result ( n=10)
Note: *p<0.01, ##p<0.01
As shown in Table 11, administration group 1 compares with model group ##p<0.01, illustrate that the present composition obviously can shorten the incubation period of learning training and recall tests, and reduce errors number, the visible present composition can improve the ability of learning and memory of vascular dementia rats.
Conclusion: the present composition significantly can improve the ability of learning and memory that permanent ligation bilateral common carotid arteries makes vascular dementia rats, therefore has protective effect to vascular dementia rats.
Embodiment 5 present composition is tested stress depression animal protection Effect study
First letting animals feed 1 week in quiet, warm environment before Wistar rat experiment, all single cage raising except matched group, natural lighting, well-ventilated, ad lib water.
Chronic mild Unpredictability stress (CUMS) depression model production program: 2h behavior is limited, 4 DEG C of frozen water went swimming 5min, the 24h that cut off the water, food 24h, folder tail 1min, light and shades puts upside down 24h, electric shock vola 5s (30V voltage), rock 5min (160Hz), 40 DEG C of environment 5min etc. nine kinds stimulates random arrangement in 18 days, every day is a kind of, makes animal can not expect the generation stimulated.Wistar rat is divided at random lasting 21 days of Normal group, depression model group, fluoxetine positive controls, Chinese medicine extract administration group 1,2,3 (20g crude drug/kg, 10g crude drug/kg and 5g crude drug/kg) (medication is with embodiment 2), each treated animal is sacrificed by decapitation after last administration 24h.
Experimental index measures
Behavioristics measures---and Morris water maze is tested
The training and testing of spatial memory carries out with reference to Morris water Maze method.Water temperature remains on about 23 DEG C, and water is dyed to white, with hidden platform.In experimentation, ambient environmental conditions is kept quite, is stablized.
Experiment is divided into training period and testing period, and 1-4d is training period.During training, rat is put into water back to platform, the escape latency of record rat, namely enters water to the time found required for hidden platform under water from rat, if do not find platform in rat 60s, guides rat to find platform.Escape latency is in 60s, and rat is found or is directed into after on platform and stops 20s, then dries and puts back in cage.Every rat enters water level and puts and convert successively in the direction of the clock, every twice training interval 30s, and the training of the second day comparatively first day quadrant that advances enters water, and the rest may be inferred.5th, 7d is the testing period, removes platform during test.The flat roof area time ratio of rat is all recorded in twice test, and the time of namely swimming across original platform place quadrant in rat 60s accounts for total time the ratio of (60s).
Adopt one factor analysis of variance (One-WayANOVA) analysis, P<0.05 thinks to have statistical significance.Experimental result is in table 12.
Table 12 each group rat training period average escape latency ( n=12)
Note: *p<0.01, #p<0.05
As shown in Table 12, administration group compares with model group: #p<0.05, after illustrating that rat gives the present composition, its escape latency obviously shortens, and namely the present composition can improve the ability of learning and memory of stress depression rat.
The mensuration of Biochemical Indexes---monoamine oxidase, MAO (MAO), glutathione S-transferase (GST), γ paddy amine acyltransferase (γ-GT)
After Wistar rat carries out last process, by rat sacrificed by decapitation, on ice pan, be separated rapidly the cerebral cortex of rat, excision low brain stem.10% brain homogenate is made in normal saline 1: 9 homogenate in ice-water bath with 0.86% pre-cooling after weighing, and after each specimen subpackage several parts, cryogenic refrigerator is frozen for subsequent use.Take out the homogenate for preparing thaw after 3000r/min, centrifugal 15min obtains homogenate supernatant, according to method shown in test kit description, adopts Chromogenic assay to measure the enzymatic activity of MAO, GST, γ-GT respectively.It the results are shown in Table 13.
Table 13 each rat cerebral even slurry biochemical indicator testing result ( n=12)
Note: *p<0.01, #p<0.05, ##p<0.01
As shown in Table 13, administration group compares with model group: #p<0.05, ##p<0.01, illustrates that the present composition can significantly improve the activity of monoamine oxidase, MAO (MAO), glutathione S-transferase (GST), γ paddy amine acyltransferase (γ-GT).
Conclusion: the present composition has certain protective role to chronic stress depression rat
Embodiment 6 present composition is tested bacterial meningitis animal protection Effect study
Bacterial meningitis model is set up
Laboratory animal
Because bacterial meningitis sickness rate in infant is higher, be the serious acute infectious diseases of neonatal period, so bacterial meningitis laboratory animal adopts 11 age in days SD neonate rats.
Pathogenic bacterium: GBSIII strain is purchased from Chinese pharmaceutical biological product test sensitivity institute
Dry strain is in serum broth after 37 DEG C of cultivation 24h, and streak inoculation, in blood plate, after 18-24h, selects single bacterium colony in serum broth, receives bacterium to mid log phase.Adopt OD value and 0.5 standard opacity tube (concentration 1 × 10 that turbidimetry adjustment bacterial concentration is corresponding 8cfu/ml) identical, show that bacterial concentration is 10 8cfu/ml.With normal saline, antibacterial is diluted to desired concn 10 4cfu/ml.
Model is set up
1) experimental group SD neonate rat 1.0% pentobarbital sodium (15-25mg/kg) intraperitoneal injection of anesthesia.Hold the vertical inserting needle of 10ul puncture needle 2-4mm recess (cerebellomedullary cistern) after neonate rat two have sharp ears line mid point, have after obviously breaking through sense, pumpback is shown in that limpid cerebrospinal fluid (CSF) flows out, and extracts 10ulCSF out and discards.Experimental group slowly injects GSBIII bacteria suspension 10ul.Whole process completes 1, in 2min, postoperative flat sleeping, puts room temperature 25 DEG C, after recovering, puts back to mouse cage and continued to feed by female Mus.After cultivating certain hour, experimental group CSF is extracted out, through process, be divided into the brain injection liquid being mixed with CSF stock solution, cefotaxime+CSF, Chinese medicine extract 20g crude drug/kg+CSF of the present invention, the several difference group of Chinese medicine extract 10g crude drug/kg+CSF of the present invention, Chinese medicine extract 5g crude drug/kg+CSF of the present invention.
2) getting newborn SD rat random packet is: blank group, model group, positive controls, administration group 1,2,3.With 1.0% pentobarbital sodium (15-25mg/kg) intraperitoneal injection of anesthesia.Hold the vertical inserting needle of 10ul puncture needle 2-4mm recess (cerebellomedullary cistern) after neonate rat two have sharp ears line mid point, have after obviously breaking through sense, pumpback is shown in that limpid cerebrospinal fluid (CSF) flows out, extract 10ulCSF out to discard, mutually commensurability CSF stock solution, cefotaxime+CSF, Chinese medicine extract 20g crude drug/kg+CSF of the present invention (administration group 1), 10g crude drug/kg+CSF (administration group 2), 5g crude drug/kg+CSF (administration group 3) is injected respectively to each group.Postoperative flat sleeping, put room temperature 25 DEG C, after recovering, put back to mouse cage continued to feed by female Mus.
Clinicing symptom observation
After inoculated bacteria, namely carry out clinical observation, comprising: with or without lip and limbs skin cyanosis, dyspnea, bradykinesia, hypokinesia and tic etc., and occur the time point of symptom the earliest.After inoculated bacteria, 24h adopts neuroethology 5 points of methods of marking processed of Loeffler to assess neonate rat.5 points: when catching back, energy proper motion, stands up in 5s; 4 points, autonomic movement reduces, and can stand up in 5s; 3 points: >5s stands up; 2 points: can not stand up; 1 point: can not move.For animal of having a convulsion, carry out tic degree evaluation according to the epilepsy SD rat tic grade scale that Racine formulates.This standard is divided into 6 grades, 0 grade: without twitching; I level: facial clonic spasm; II level: on the basis of I level, has the rhythm and pace of moving things to nod; III level: have forelimb clonic spasm on the basis of II level; IV level: have hind leg station power on the basis of III level; V level: IV level obtain basic on fall.
Experimental result is in table 14,15.
Table 14 is inoculated the clinical manifestation of different liquids neonate rat and is compared
As shown in Table 14, after rat gives the present composition, its each clinical symptoms obviously alleviates.
Table 15 is inoculated different liquids 24h neural behavior scoring and is compared
Note: *p<0.01, #p<0.05, ##p<0.01
As shown in Table 15, one factor analysis of variance (One-Way ANOVA) is analyzed, and model group compares with blank group: *p<0.01 illustrates modeling success; Administration group compares with model group: #p<0.05, ##p<0.01, illustrates that administration group significantly improves compared with the neurobehavioral of model group, and the visible present composition obviously can improve the neurobehavioral of meningitis rat.
The rat still survived after during inoculation 24h, get 10ul CSF through cisternal puncture again before execution and make WBC (leukocyte calculating) counting, count results is as following table 16:
Table 16WBC result of calculation
Note: *p<0.01, #p<0.05, ##p<0.01
As shown in Table 16, one factor analysis of variance (One-way ANOVA) is analyzed, and model group compares with blank group: *p<0.01, illustrates modeling success; Administration group compares with model group: #p<0.05, ##p<0.01, illustrates that the present composition can obviously reduce rat white blood cell count, reduces the inflammation of meningitis rat.
Conclusion: the antibacterial action that the present composition has had, has certain improvement result to bacterial meningitis animal symptom.

Claims (12)

1. a Traditional Chinese medicine compound composition, described Chinese medicine is made up of Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae, it is characterized in that described Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae weight ratio be 3:2:2-0.5.
2. Traditional Chinese medicine compound composition according to claim 1, it is characterized in that described Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae weight ratio be 3:2:2-1.
3. Traditional Chinese medicine compound composition according to claim 2, it is characterized in that described Radix Ginseng, Rhizoma Coptidis, Fructus Gardeniae weight ratio be 3:2:2.
4. a traditional Chinese medicine extract composition, it is made up of Radix Ginseng extract, Rhizoma Coptidis extract, Fructus Gardeniae extract, it is characterized in that the weight ratio of described Radix Ginseng extract, Rhizoma Coptidis extract, Fructus Gardeniae extract is 3:2:2-0.5.
5. traditional Chinese medicine extract composition according to claim 4, is characterized in that the weight ratio of described Radix Ginseng extract, Rhizoma Coptidis extract, Fructus Gardeniae extract is 3:2:2-1.
6. traditional Chinese medicine extract composition according to claim 5, is characterized in that the weight ratio of described Radix Ginseng extract, Rhizoma Coptidis extract, Fructus Gardeniae extract is 3:2:2.
7. a pharmaceutical preparation, it comprises compositions according to any one of claim 1 ~ 6 as active component and any one or multiple pharmaceutically acceptable carrier.
8. pharmaceutical preparation according to claim 7, it is the pharmaceutically acceptable dosage form of any one.
9. the purposes of the compositions according to any one of claim 1 ~ 6 in the medicine of preparation treatment or prevention brain and nerve injury, nervus retrogression encephalopathy, bacillary or viral encephalitis or depression.
10. purposes according to claim 9, wherein said brain and nerve injury are cerebrovascular dementia or ischemic cerebrovascular.
11. purposes according to claim 10, wherein said ischemic cerebrovascular is the outbreak of transience local cerebral ischemia, cerebral infarction or apoplexy.
12. purposes according to claim 9, wherein said nervus retrogression encephalopathy is senile dementia or Parkinson's disease.
CN201280002971.9A 2011-07-05 2012-06-28 Composition of chinese herbal compound or extract and use thereof Active CN103108645B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201280002971.9A CN103108645B (en) 2011-07-05 2012-06-28 Composition of chinese herbal compound or extract and use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201110186423.3 2011-07-05
CN2011101864233A CN102861152A (en) 2011-07-05 2011-07-05 Chinese medicine compound or composition of its extract and application thereof
CN2011101864233 2011-07-05
CN201280002971.9A CN103108645B (en) 2011-07-05 2012-06-28 Composition of chinese herbal compound or extract and use thereof
PCT/CN2012/077793 WO2013004145A1 (en) 2011-07-05 2012-06-28 Composition of chinese herbal compound or extract and use thereof

Publications (2)

Publication Number Publication Date
CN103108645A CN103108645A (en) 2013-05-15
CN103108645B true CN103108645B (en) 2015-07-15

Family

ID=47436507

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011101864233A Pending CN102861152A (en) 2011-07-05 2011-07-05 Chinese medicine compound or composition of its extract and application thereof
CN201280002971.9A Active CN103108645B (en) 2011-07-05 2012-06-28 Composition of chinese herbal compound or extract and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2011101864233A Pending CN102861152A (en) 2011-07-05 2011-07-05 Chinese medicine compound or composition of its extract and application thereof

Country Status (2)

Country Link
CN (2) CN102861152A (en)
WO (1) WO2013004145A1 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
吕茂平.复方栀子注射液的制剂学及质量标准研究.《中国优秀硕士学位论文全文数据库,医药卫生科技辑》.2003,(第2期),21,36-37. *
小檗碱对缺血性脑损伤保护作用的实验研究;潘力雄等;《广东解剖学通报》;19951231;第17卷(第2期);81-84 *

Also Published As

Publication number Publication date
CN102861152A (en) 2013-01-09
CN103108645A (en) 2013-05-15
WO2013004145A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
CN103893549A (en) Traditional Chinese medicine composition for relieving fatigue as well as preparation method and application of composition
CN101062080B (en) Medicinal composition for relieving fatigue and preparing process thereof
CN103520505B (en) Traditional Chinese medicine preparation for treating neurasthenia and preparation method thereof
CN103108639B (en) Composition of active ingredient of traditional chinese medicine and use thereof
CN104547532A (en) Traditional Chinese medicine preparation for treating migraine and preparation method of traditional Chinese medicine preparation
CN101780227A (en) Traditional Chinese medicine composition for treating acute stroke and preparation method thereof
CN105148220A (en) Traditional Chinese medicine for treating spleen-kidney yang deficiency type dizziness and preparation method of traditional Chinese medicine
CN101732585A (en) Medicinal composition for treating migraine, preparation method and application thereof
CN103108645B (en) Composition of chinese herbal compound or extract and use thereof
CN104623068B (en) Treat medicine of fever in children infantile convulsion and preparation method thereof
CN104095938B (en) A kind of Mongolian medicinal preparation of Cure of depression
CN103550477B (en) Medicament for treating herpes zoster
CN104258224A (en) Schisandra chinensis oral solution for treating lung-and-kidney yin-deficiency type chronic bronchitis and preparation method thereof
CN108379367A (en) Pure Chinese medicine drug of drug rehabilitation and preparation method thereof
CN115554372B (en) Traditional Chinese medicine for treating primary fibromyalgia syndrome and preparation method and application thereof
CN104740210B (en) A kind of Chinese medicine and preparation method for the treatment of qi stagnation and blood stasis type craniocerebral trauma syndrome
CN110478450B (en) Pharmaceutical composition for treating Alzheimer disease and application thereof
CN101244127B (en) Medicament for treating vascular dementia
CN105749021A (en) Chinese medicine preparation for treating chronic glomerulonephritis
CN105031286A (en) Chinese herb preparation for treating iron-deficiency anemia and preparation method thereof
CN105770563A (en) Traditional Chinese medicine preparation for treating anxiety disorder and preparation method for traditional Chinese medicine preparation
CN105477550A (en) Traditional Chinese medicine preparation for treating involutional melancholia and preparation method thereof
CN104887964A (en) Traditional Chinese medicine for treating phlegm-accumulation vein-resistance type vertigo and preparation method of traditional Chinese medicine
CN104784331A (en) Traditional Chinese medicine for treating dilated cardiomyopathy and preparation method thereof
CN104586974A (en) Traditional Chinese medicine for treating lung-heat cough

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant